Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

RCT (n=1132) found treatment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations and cardiovascular death vs placebo (RR 0·80, 95% CI 0·64–1·00, p=0·050) in patients with acute heart failure with a left ventricular ejection fraction <50%.

The Lancet